Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Nonsteroidal anti-inflammatory drugs and prostatic diseases.

Ishiguro H, Kawahara T.

Biomed Res Int. 2014;2014:436123. doi: 10.1155/2014/436123. Epub 2014 May 12. Review.

2.

Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Schenk JM, Calip GS, Tangen CM, Goodman P, Parsons JK, Thompson IM, Kristal AR.

Am J Epidemiol. 2012 Jul 15;176(2):156-63. doi: 10.1093/aje/kwr524. Epub 2012 Jun 28.

3.

Nonsteroidal anti-inflammatory drugs and other analgesic use and bladder cancer in northern New England.

Baris D, Karagas MR, Koutros S, Colt JS, Johnson A, Schwenn M, Fischer AH, Figueroa JD, Berndt SI, Han S, Beane Freeman LE, Lubin JH, Cherala S, Cantor KP, Jacobs K, Chanock S, Chatterjee N, Rothman N, Silverman DT.

Int J Cancer. 2013 Jan 1;132(1):162-73. doi: 10.1002/ijc.27590. Epub 2012 May 22.

4.

Nonsteroidal antiinflammatory drug use and lower urinary tract symptoms: results from the Boston area community health survey.

Gates MA, Hall SA, Chiu GR, Kupelian V, Fitzgerald MP, Link CL, McKinlay JB.

Am J Epidemiol. 2011 May 1;173(9):1022-31. doi: 10.1093/aje/kwq473. Epub 2011 Feb 28.

5.
6.

Acute urinary retention in benign prostatic hyperplasia: Risk factors and current management.

Muruganandham K, Dubey D, Kapoor R.

Indian J Urol. 2007 Oct;23(4):347-53. doi: 10.4103/0970-1591.35050.

7.

The Norwegian General Practice (NORGEP) criteria for assessing potentially inappropriate prescriptions to elderly patients. A modified Delphi study.

Rognstad S, Brekke M, Fetveit A, Spigset O, Wyller TB, Straand J.

Scand J Prim Health Care. 2009;27(3):153-9. doi: 10.1080/02813430902992215.

8.

Supplemental Content

Support Center